Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ETOPOSIDE

All products: general benefit

Other products in the same Health Canada class (L01C) — coverage varies; not interchangeable

  • Vincristine (Oncovin): general benefit, Not a benefit

Vepesid · DIN 00616192 · 50mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Vepesid · DIN 00616192 Manufacturer: Cheplapharm Arzneimittel GmbH; listing date 1996-10-01 Health Canada: Marketed since 2020-01-02 · brand VEPESID · ATC L01CB01 ETOPOSIDE · form Capsule · route Oral · ingredients ETOPOSIDE 50 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Vepesid: Formulary list price $48.7570/unit (unit not stated in source; not the patient's cost)

Ministry pays: $48.7570 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5963 · Verify on the e-Formulary ↗ (DIN 00616192)

Source record
DIN 00616192: Vepesid Raw flags: sec3=Y Item: 100000072; group id 158; item number 0271; lccId None; manufacturer id CHE Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $48.7570; ministry $48.7570 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00616192 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5963
Shortage status: anticipated shortage (last updated 2026-08-25) · Tier 3; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00616192
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

VINCRISTINE SULFATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1mg/mL · Inj Sol

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

CYCLOPHOSPHAMIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg, 50mg · Tab

CYPROTERONE ACETATE

· 4 products · General benefit · strengths: 50mg · Tab

DAUNORUBICIN

· 1 products · General benefit · strengths: · Inj Pd-20mg Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS VEPESID (etoposide) is indicated for: Small Cell Carcinoma of the Lung • first-line therapy in combination with other established antineoplastic agents. • second-line combination or single agent therapy in patients who have not responded or relapsed on other chemotherapeutic regimens. Malignant Lymphoma (histiocytic type) • first-line therapy in combination with other established antineoplastic agents. Non-small Cell Carcinoma of the Lung • for patients considered ineligible for surgery, etoposide has been shown effective alone or in combination with PLATINOL (cisplatin). • for patients who require chemotherapy following surgery. Testicular Malignancies (germ cell tumours including seminomas) • in combination with other effective chemotherapeutic agents in patients who have already received appropriate therapy. 1.1 Pediatrics Pediatrics(<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: No data are available to Health Canada; therefore, Health … https://pdf.hres.ca/dpd_pm/00076442.PDF PM date: December 31, 1984 Source product: VEPESID; DIN 00616192; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.